Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylone in PTSD
NCT06237426Phase 2Completed
- Sponsor
- Transcend Therapeutics
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of methylone in post-traumatic stress disorder (PTSD), sponsored by Transcend Therapeutics. Primary endpoint: Clinician Administered PTSD Scale for DSM-5 Total Severity at 52 weeks. Started Mar 2024; status: completed.
02
Drugs
methylone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06237426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237426.